Best Agrolife Limited — Q1 FY26 earnings call

Call held 8 Aug 2025

Management summary

Best Agrolife reported a strategic shift in Q1 FY26, prioritizing profitability and patented products over early placements, leading to a 26.4% YoY revenue decline to ₹382 crores. Despite this, gross margins improved to 30% and EBITDA margin expanded to 12%. The company saw significant reduction in sales returns and is optimistic about future margin expansion and new product contributions.

Highlights

  • Gross margin improved to 30% from 24% YoY, reaching ₹111 crores.

  • EBITDA margin expanded by 140 basis points to 12% in Q1 FY26.

  • PAT margin increased to 5% from 4% in Q1 FY25, with PAT stable at ₹20 crores.

  • Patented products' contribution to brand sales increased to 45% from 29% last year.

  • Actual sales returns significantly reduced to ₹13 crores in Q1 FY26, compared to ₹35-40 crores in Q1 FY25.

Concerns

  • Revenue declined by 26.4% YoY to ₹382 crores in Q1 FY26 due to a strategic shift in sales policy.

  • EBITDA decreased to ₹46 crores in Q1 FY26 from ₹55 crores in Q1 FY25.

Key financials

  1. Revenue ₹382 Cr -26.4%YoY
  2. Gross Margin ₹111 Cr
  3. Gross Margin Percentage 30%
  4. EBITDA ₹46 Cr
  5. EBITDA Margin 12%
  6. PAT ₹20 Cr
  7. PAT Margin 5%
  8. Sales Return Provision ₹50 Cr
  9. Actual Sales Return ₹13 Cr
  10. Patented Portfolio Share of Brand Sales 45%

What they filed

Q1 FY27: revenue up 3.9%, net profit up 105.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue747 274 274 381 517 −31%203 −26%156 −43%396 +4%
EBITDA147 -6 4 46 78 −47%4 +167%-27 −775%78 +70%
Net profit95 -24 -22 20 39 −59%-13 +46%-37 −68%41 +105%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Capex ₹90 Cr ₹60 crores funded by a financer
    • Additional plant in Gajraula facility ₹90 Cr
    So on the CAPEX part we should be starting anytime. So it is a project of Rs. 90 crores wherein funded by a financer by Rs. 60 crores. So that will start anytime now. For the other sales return related part this Rs. 50 crores, since there is a little bit delay in the season, what we are expecting either it should be by September or October we should have an idea about the actual sales returns.

Guidance & targets

Revenue

  • Annual Revenue Revenue · FY26-27 · High confidence ₹1,600-1,700 crores
    We are targeting a conservative annual revenue for FY'26-27, which can be in the range of Rs. 1,600 crores to Rs. 1,700 crores

    — Vikas Jain

Profitability

  • Annual EBITDA Margin Profitability · FY26-27 · High confidence Exceed 15% plus
    with an annual EBITDA margin expected to exceed 15% plus.

    — Vikas Jain

  • Q2 EBITDA Margin Profitability · Q2 FY26 · High confidence Much higher than 17%, 18%
    this quarter, we will see a huge jump in the gross margin as well as EBITDA, much higher than 17%, 18%. So, this will take care of the 15% plus for the year.

    — Vikas Jain

Sales

  • Annual Sales Return Percentage Sales · FY26-27 · High confidence Not more than 10% to 12%

    Previously 20% to 24% → Not more than 10% to 12%

    for sales return, since last two years, we have been facing this issue of anywhere between 20% to 24% of sales return. So, this year, our target is not to have more than 10% to 12%.

    — Vikas Jain

Operating Expenses

  • Annual OPEX Reduction Operating Expenses · FY26-27 · High confidence ₹30-40 crores
    our OPEX will be lesser by anywhere between Rs. 30 crores to Rs. 40 crores compared to last year.

    — Vikas Jain

New Product Launches

  • New Product Launch New Product Launches · Q2 FY26 · High confidence Bestman
    This Quarter 2 definitely we are launching our Shot down and in fact we have launched but sales will start in the Quarter 2 only for our Bestman product.

    — Vimal Kumar

  • New Product Launch New Product Launches · Q3 FY26 · High confidence One more product
    Also, I mentioned there is one more product that we will launch in Quarter 3.

    — Vimal Kumar

What to watch in Q2 FY26

Q2 Revenue Performance

next quarter
Current Q1 FY26 revenue down 26.4% YoY to ₹382 crores
Target Revenue pickup in Q2, aligned with seasonal trends

Why it matters

To verify if the strategic shift in sales policy (deferring placements) leads to the expected revenue recovery in Q2.

Looking ahead, we anticipate a revenue pickup in Q2, aligned with seasonal trends and a delayed carry swing.

Risks & concerns

  • Monsoon variability impacting showing activity

    medium

    Mixed monsoon season with normal to above normal rainfall in most parts, but variability in certain regions impacted showing activity.

    Management acknowledged

  • Lower Q1 revenue due to strategic shift in sales policy

    medium

    Strategic decision to implement revised sales policies, reducing early product placement to focus on in-season sales, resulted in lower Q1 revenue.

    Management acknowledged

  • Longer registration time for international patented products

    medium

    Registration for new molecules and formulations in international markets takes longer due to extensive field trials and regulatory processes.

    Management acknowledged

  • Delay in season, especially in the South

    low

    A considerable delay in the season, particularly in South India, impacted Q1 sales, but sales are expected to shift to Q2 and Q3.

    Management acknowledged

  • Chilli market issues and reduced cotton acreage

    low

    Chilli prices have issues and cotton acreage is less, but management states it does not significantly impact their overall business due to their market share and market scope.

    Analyst downplayed

Q&A highlights

7 direct
Focus on technical sales vs. branded sales Direct
If we talk about the technical sales, their margin will be very less. So, we are now moving towards a profitable organization rather than keeping only the sales revenues.

Clarifies the company's strategic shift from volume-driven technical sales to higher-margin branded products, explaining the Q1 revenue dip.

Asked by Hemant

Supply of patented products to other B2C players Direct
first we have to establish and make it as a big brand in the farmers and dealer-distributor, then only we will give to some of the co-partners like big companies because many small companies, many mid-size companies are asking us, but we are always aiming, you know, for the MNCs company or like that.

Indicates a cautious, long-term brand-building strategy for patented products before wider B2B distribution, suggesting a slower but more valuable ramp-up.

Asked by Hemant

Impact of Chilli market and Cotton acreage on Q3/Q4 revenue Direct
Q1 generally do not have any kind of sales in South India... But that does not make any big difference. The market still has a big scope for both the products, cotton and chilli. Not at all, Mr. Hemant. This is not like that way. Because our total market share is not that big, that it will influence it directly.

Addresses concerns about specific crop market conditions, clarifying that the Q1 revenue dip is strategic and not primarily due to these external factors.

Asked by Hemant

Impact of strategic recalibration on Q2 revenue and FY27 growth Direct
for full year, even though we will not have the growth, but what we will have is a drastic increase in our gross margins and a huge improvement in our profitability. This is what will happen. With respect to top line, there will be recalibration of the top line throughout the quarters.

Confirms the strategic shift's impact on revenue phasing and clarifies that while full-year revenue might not grow, profitability is expected to improve significantly.

Asked by Nishant Bhat

Sales return percentage factored into FY26-27 revenue guidance Direct
for sales return, since last two years, we have been facing this issue of anywhere between 20% to 24% of sales return. So, this year, our target is not to have more than 10% to 12%.

Provides crucial context for the revenue guidance, highlighting the expected positive impact of improved sales return policies on net revenue.

Asked by Saket Kapoor

Path to achieving 15%+ annual EBITDA margin given Q1's 12% Direct
this quarter, we will see a huge jump in the gross margin as well as EBITDA, much higher than 17%, 18%. So, this will take care of the 15% plus for the year.

Explains how the company plans to achieve its full-year EBITDA margin guidance, linking it to product mix and sales phasing in subsequent quarters.

Asked by Saket Kapoor

Status of new CAPEX and sales return provision Direct
on the CAPEX part we should be starting anytime. So it is a project of Rs. 90 crores... will take close to one year for us to get this completed. So the benefit of it which will only come in 26-27. For the other sales return related part this Rs. 50 crores... by September or October we should have an idea about the actual sales returns.

Provides timelines for CAPEX and clarifies the nature and expected resolution of the sales return provision, impacting future profitability and capacity.

Asked by Saket Kapoor

Lack of press releases for new products/patents in Q1 Partial
we continue to put all those press releases in the market whenever we get the patents... we had done enough not only the press releases but also in the field itself doing all the trials.

Highlights a potential communication gap or change in strategy regarding public announcements, which could affect investor awareness and perception.

Asked by Sanjay

2 min read 6 chapters

Detailed narrative

Strategic Shift Towards Profitability and Patented Products

Best Agrolife has implemented a strategic shift in its sales policy, moving from early product placement to focusing on in-season sales and patented molecules. This aims to enhance profitability, reduce excess inventory, and lower sales returns. This strategic decision led to a 26.4% YoY decline in Q1 FY26 revenue to ₹382 crores from ₹519 crores in Q1 FY25. The company believes this is a critical step towards a more sustainable business model, with benefits expected in subsequent quarters.

Improved Margins Despite Revenue Decline

Despite the year-on-year dip in revenue, the company's profitability improved significantly due to a richer product mix and disciplined pricing. Gross margins for Q1 FY26 stood at ₹111 crores, with the margin percentage improving to 30% from 24% in Q1 FY25. EBITDA for the quarter was ₹46 crores, down from ₹55 crores YoY, but the EBITDA margin expanded by 140 basis points to 12%. Profit after tax remained stable at ₹20 crores, with the PAT margin increasing to 5% from 4% in Q1 FY25.

New Product Launches and Patent Portfolio Expansion

Best Agrolife successfully launched new patented products like 'Shot Down' (a soybean herbicide) and 'Bestman,' which are performing well in their debut season. The company secured two new patents in Q1 FY26 for novel insecticide-fungicide combinations, offering broad-spectrum pest and disease control. Additionally, new FIM registrations were obtained for 'Cubax Power Extra' and 'Trishanku,' targeting various pests and crops, reinforcing the focus on innovation-led growth.

Enhanced Inventory Management and Reduced Sales Returns

The revised sales policies have led to a significant reduction in sales returns, contributing to improved inventory hygiene and enhanced profitability. In Q1 FY26, actual sales returns were only ₹13 crores, a substantial decrease from ₹35-40 crores in Q1 FY25. The company made a conservative provision of ₹50 crores for sales returns in Q1, anticipating a potential reversal if actual returns remain low, which would further boost profitability.

International Business Expansion and Global Patents

The company is actively expanding its international footprint, having completed assignments in an African nation and initiating registration processes for patented products in Sri Lanka and nano-urea in Australia and Mauritius. Global patent filings were made in key jurisdictions such as the US, EU, UAE, Brazil, Vietnam, Egypt, and Indonesia. This strategy focuses on innovation-led international growth, leveraging the company's technical manufacturing capabilities for global markets.

FY26 Capex Plans and Future Outlook

Best Agrolife plans a CAPEX of ₹90 crores for FY26, with ₹60 crores funded by a financer, for an additional plant at its Gajraula facility. This plant is expected to be completed in one year, with benefits accruing from FY27. The company targets an annual revenue of ₹1,600-1,700 crores for FY26-27 with an EBITDA margin exceeding 15% plus, driven by product innovation, margin improvement, and operational efficiency.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls